To the supplement on molecular biomarkers and indications (german)<\/a>[\/et_pb_text][dvmd_table_maker tbl_top_left_mode=”on” tbl_responsive_breakpoint=”max_width_767″ tbl_responsive_display_as=”accordion” tbl_chead_cell_color=”#0082B0″ tbl_rhead_cell_color=”#0082B0″ tbl_chead_text_wrap=”normal” tbl_chead_text_level_active=”on” tbl_chead_text_level=”h2″ tbl_rhead_text_level_active=”on” tbl_rhead_text_level=”h2″ _builder_version=”4.27.4″ _module_preset=”default” tbl_tcell_text_font_size=”17px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][dvmd_table_maker_item col_label=”Genes” col_content=”Genes
\nAKT1
\nAKT1
\nAKT1
\nALK
\nALK
\nALK
\nALK
\nALK
\nALK
\nALK
\nATM
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRAF
\nBRCA1 \/ BRCA2
\nBRCA1 \/ BRCA2
\nBRCA1 \/ BRCA2
\nBRCA1 \/ BRCA2
\nBRCA1 \/ BRCA2
\nCTNNB1
\nEGFR *
\nEGFR *
\nEGFR *
\nEGFR *
\nEGFR *
\nEGFR *
\nERBB2
\nERBB2
\nERBB2
\nERBB2
\nERBB2
\nERBB2
\nESR1
\nFGFR2
\nFGFR2
\nFGFR2
\nFGFR3
\nFGFR3
\nFGFR3
\nHomologous Recombination Deficiency
\nHRAS
\nIDH1
\nIDH2
\nKIT
\nKIT
\nKIT
\nKRAS
\nMAP2K1
\nMAP2K1
\nMAP2K1
\nMET
\nMET
\nMET
\nMET
\nMET
\nMET
\nMET
\nMikrosatelliten-instabilit\u00e4t
\nMTOR
\nMTOR
\nMTOR
\nNRAS
\nNTRK1
\nNTRK1
\nNTRK2
\nNTRK3
\nNTRK3
\nPDGFRA
\nPDGFRA
\nPDGFRA
\nPDGFRA
\nPIK3CA
\nPIK3CA
\nPTEN
\nRET
\nRET
\nRET
\nROS1
\nTumor Mutation Burden” col_column_max_width=”0fr” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/dvmd_table_maker_item][dvmd_table_maker_item col_label=”Change” col_content=”Change
\nMutation E17K
\nMutation E17K
\nMutation E17K
\nMutation, Fusion, Amplifikation
\nMutation C1156Y
\nMutation I1171N
\nMutation L1196M
\nMutation G1202R
\nMutation G1269A
\nFusions<\/p>\nMutation (V600E)<\/p>\n
Mutation (V600)<\/p>\n
Mutation G464, G469, L597, K601
\nK601
\nFusions
\nFusions
\nInactivating variants<\/p>\n
Mutation
\nActivating mutations (e.g., exon 19 deletions, L858R, etc.)
\nExon 20 Insertion, T790M
\nT790M
\nExon 20 Insertion
\nD761Y
\nC797
\nAmplifications
\nAmplifications
\nAmplifications<\/p>\n
Activating mutations
\nActivating mutations
\nMutations
\nFusions
\nFusions
\nActivating mutations
\nFusions
\nActivating mutations
\nActivating mutations
\nGenomic instability (HRD score high)
\nActivating mutations
\nActivating mutations<\/p>\n
Activating mutations, Deletions, Duplications
\nMutations V654A, T670I, C809G, D816, D820, N822, Y823D, A829P<\/p>\n
Activating mutations
\nActivating mutations<\/p>\n
Exon14 splice Mutation and Deletion, activating point mutations such as Y1003, D1010
\nAmplifikation
\nAmplifikation
\nPunkmutation D1228N
\nPunkmutation Y1230H
\nAmplifications
\nFusions
\nMSI high
\nL1460P, L2209V, L2427Q
\nE2014K E2419K
\nActivating mutations
\nActivating mutations
\nFusions
\nG595R
\nFusions
\nFusions
\nG623R
\nActivating mutations, Deletions, Duplications
\nD842V
\nD842V
\nD842Y, D842_H845del, D842_H845insV
\nActivating mutations
\nActivating mutations
\nInactivating mutations
\nActivating mutations
\nFusions
\nFusions
\nFusions
\nTMB high ({{gt}}10 mut\/Mb)” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/dvmd_table_maker_item][dvmd_table_maker_item col_label=”Common tumor types” col_content=”Common tumor types
\nBreast cancer
\nEndometrial cancer
\nOvarian cancer
\nNon-small cell lung cancer
\nNon-small cell lung cancer
\nNon-small cell lung cancer
\nNon-small cell lung cancer
\nNon-small cell lung cancer
\nNon-small cell lung cancer
\nInflammatory myofibroblastic tumor
\nProstate carcinoma
\nColorectal carcinoma
\nAnaplastic thyroid carcinoma
\nPleomorphic xanthoastrocytoma
\nGanglioglioma
\nPilocytic astrocytoma
\nMelanoma
\nNon-small cell lung carcinoma
\nAnaplastic thyroid carcinoma
\nAll solid malignancies
\nMelanoma
\nMelanoma
\nOvarian carcinoma
\nOvarian carcinoma
\nOvarian-fallopian tube-peritoneal carcinoma
\nBreast carcinoma
\nPancreatic carcinoma
\nProstate carcinoma
\nDesmoid fibromatosis
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nBreast carcinoma
\nGastric carcinoma
\nSerous endometrial carcinoma
\nColorectal carcinoma
\nBreast carcinoma
\nNon-small cell lung carcinoma
\nBreast carcinoma
\nBladder carcinoma
\nCholangiocellular carcinoma
\nAll solid malignancies
\nBladder carcinoma
\nBladder carcinoma
\nAll solid malignancies
\nOvarian, fallopian tube, peritoneal carcinoma
\nSquamous cell carcinoma, head and neck
\nCholangiocellular carcinoma
\nCholangiocellular carcinoma
\nGastrointestinal stromal tumor
\nGastrointestinal stromal tumor
\nMelanoma
\nColorectal carcinoma
\nMelanoma
\nNon-small cell lung carcinoma
\nLow-grade serous ovarian carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nNon-small cell lung carcinoma
\nRenal cell carcinoma
\nAll solid malignancies
\nAll solid malignancies
\nRenal cell carcinoma
\nBladder carcinoma
\nAll solid malignancies
\nColorectal carcinoma,
\nAll solid malignancies
\nAll solid malignancies
\nAll solid malignancies
\nAll solid malignancies
\nAll solid malignancies
\nGastrointestinal stromal tumor
\nGastrointestinal stromal tumor
\nGastrointestinal stromal tumor
\nGastrointestinal stromal tumor
\nBreast carcinoma
\nFollicular and papillary thyroid carcinoma
\nAll solid malignancies
\nMedullary thyroid carcinoma
\nNon-small cell lung carcinoma
\nThyroid carcinoma
\nNon-small cell lung carcinoma
\nAll solid malignancies” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/dvmd_table_maker_item][dvmd_table_maker_item col_label=”Medicines approved in Germany” col_content=”Medicines approved in Germany<\/p>\n
Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib<\/p>\n
Binimetinib, Cobimetinib, Dabrafenib, Encorafenib, Trametinib, Vemurafenib<\/p>\n
Dabrafenib + Trametinib<\/p>\n
Olaparib
\nRucaparib, Niraparib
\nTalazoparib, Olaparib
\nOlaparib
\nOlaparib<\/p>\n
Dacomitinib, Erlotinib, Gefitinib, Osimertinib
\nResistenz Afatinib, Erlotinib, Gefitinib
\nOsimertinib<\/p>\n
Trastuzumab, Trastuzumab Deruxtecan, Lapatinib + Trastuzumab, Pertuzumab + Trastuzumab, Tucatinib + Capecitabine + Trastuzumab, Ado-Trastuzumab Emtansine, Lapatinib, Neratinib
\nTrastuzumab<\/p>\n
Olaparib+Bevaciumab<\/p>\n
Imatinib, Regorafenib, Sunitinib,<\/p>\n
Imatinib
\nResistenz, Panitumumab, Cetixumab<\/p>\n
Resistenz, Panitumumab, Cetixumab
\nLarotrectinib Entrectinib<\/p>\n
Larotrectinib Entrectinib
\nLarotrectinib Entrectinib<\/p>\n
Imatinib, Regorafenib, Sunitinib,<\/p>\n
Avapritinib<\/p>\n
Alpelisib (+ Fulvestrant)<\/p>\n
Vandetanib<\/p>\n
Crizotinib Entrectinib
\n” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/dvmd_table_maker_item][dvmd_table_maker_item col_label=”Off label\/Studies” col_content=”Off label\/Studies
\nAZD5363 (Capivasertib)
\nAZD5363 (Capivasertib)
\nAZD5363 (Capivasertib)
\nAfatinib, Dacomitinib, Erlotinib, Gefitinib, Pembrolizumab
\nResistenz Crizotinib
\nResistenz Alectinib
\nResistenz Crizotinib
\nResistenz Alectinib
\nResistenz Crizotinib
\nCeritinib, Crizotinib
\nOlaparib
\nEncorafenib + Cetuximab, Encorafenib + Panitumumab
\nDabrafenib + Trametinib
\nDabrafenib + Trametinib Vemurafenib + Cobimetinib
\nDabrafenib + Trametinib Vemurafenib + Cobimetinib
\nDabrafenib + Trametinib Vemurafenib + Cobimetinib<\/p>\n
pembrolizumab, and vemurafenib<\/p>\n
PLX8394
\nTrametinib
\nCobimetinib Trametinib
\nCobimetinib Trametinib<\/p>\n
Rucaparib
\ndiagnostischer Marker
\nErlotinib, Gefitinib, Afatinib, and Osimertinib<\/p>\n
Poziotinib
\nResistenz Gefitinib
\nResistenz Osimertinib<\/p>\n
Carboplatin-Taxol Regimen + Trastuzumab
\nLapatinib + Trastuzumab, Pertuzumab + Trastuzumab
\nNeratinib
\nAdo-Trastuzumab Emtansine, Neratinib
\nResistenz, anti-hormonelle Therapie
\nErdafitinib, AZD4547, BGJ398, Debio1347
\nPemigatinib
\nAZD4547, BGJ398, Erdafitinib, Debio1347
\nErdafitinib, AZD4547, BGJ398, Debio1347
\nErdafitinib, AZD4547, BGJ398, Debio1348
\nAZD4547, BGJ398, Erdafitinib, Debio1347
\nNiraparib
\nTipifarnib
\nIvosidenib<\/p>\n
Ripretinib
\nResistenz, Imatinib, Sunitinib<\/p>\n
Cobimetinib Trametinib<\/p>\n
Capmatinib, Crizotinib , Cabozantinib
\nCrizotinib
\nResistenz Erlotinib Osimertinib Gefitinib
\nCrizotinib Cabozantinib Capmatinib
\nCrizotinib Cabozantinib
\nCabozantinib
\nCrizotinib
\nPembrolizumab
\nTemsirolimus
\nEverolimus
\nTemsirolimus, Everolimus<\/p>\n
Resistenz Larotrectinib<\/p>\n
Resistenz Larotrectinib
\nRipretinib
\nResistenz Imatinib
\nDasatinib
\nAvapritinib<\/p>\n
Everolimus (+ Sorafenib)
\nGSK2636771 AZD8186
\nPralsetinib
\nPralsetinib Selpercatinib Cabozantinib Vandetanib
\nSelpercatinib<\/p>\n
Pembrolizumab” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/dvmd_table_maker_item][\/dvmd_table_maker][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
* Activating EGFR mutations are diverse. They are the subject of numerous studies that are constantly modifying treatment strategies for non-small cell lung cancer. It is not possible to provide a complete overview of the complex results here.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Current overview of relevant molecular biomarkers in molecular pathology We offer a wide range of therapy-relevant genetic testing for solid tumors. The information serves as a guide to molecular biomarkers and targeted drugs. Due to the complexity of study results and drug approvals, the completeness of the data cannot be guaranteed. Drug treatment can only […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":113195,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"dipi_cpt_category":[],"class_list":["post-113197","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/pages\/113197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/comments?post=113197"}],"version-history":[{"count":3,"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/pages\/113197\/revisions"}],"predecessor-version":[{"id":113201,"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/pages\/113197\/revisions\/113201"}],"up":[{"embeddable":true,"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/pages\/113195"}],"wp:attachment":[{"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/media?parent=113197"}],"wp:term":[{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/www.molpath-bw.de\/en\/wp-json\/wp\/v2\/dipi_cpt_category?post=113197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}